Earnings2395SHIN NIPPON BIOMEDICAL LABORATORIES,LTD.
SHIN Nippon Biomedical Reports Earnings Results
TOKYO, May 11 (Pulse News Wire) – Shin Nippon Biomedical Laboratories, Ltd. (2395.T) reported consolidated results for fiscal year 2026 ending March.
Operating profit was ¥30 million (+0.0%). net profit attributable to shareholders was ¥2,081 million (+42.3%).
Total assets stood at ¥110 billion with an equity ratio of 41.0%. The year-end dividend was set at ¥5 per share.
The full-year forecast for the current fiscal year is revenue of ¥38.0 billion (+16.8%).
Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥32,524M | +0.3% |
| Operating profit | ¥2,653M | -11.1% |
| Net profit | ¥4,566M | -7.3% |
Next period forecast
Revenue
¥38,000M
+16.8%Op. profit
¥3,000M
+13.0%Net profit
¥3,500M
-23.4%Figures in millions of yen
End of article